ASK REDCHAT ANYTHING ABOUT APREA THERAPEUTICS INC.
Aprea Therapeutics Inc. (NASDAQ: APRE)
Listen to this Section
$0.74
-0.0393
(
-5.07% )
84.7K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| ATRN-119DetailsSolid tumor/s, Cancer |
Phase 1 |
| APR-1051DetailsSolid tumor/s, Cancer |
Phase 1 |
| Eprenetapopt (APR-246) + azacitidineDetailsAcute myeloid leukemia, Cancer, Myelodysplastic syndrome |
Failed |
| Eprenetapopt (APR-246) + AzacitidineDetailsBlood disorder, Myelodysplastic syndrome |
Failed |
| APR-548 + azacitidineDetailsMutant Myelodysplastic Syndromes |
Failed |
Market Data
|
| Open |
$0.74 |
| Previous Close |
$0.78 |
| Volume |
84.7K |
| Market Cap |
$9.44M |
| Day Range |
$0.73 - $0.83 |
| 52 Week Range |
$0.55 - $2.22 |
| Shares Outstanding |
12.38M |
| Change % |
-5.07% |
| Net Change |
▼ -0.0393 |
| Insider Ownership |
0.00% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2019 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-3,798,626.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2026-04-01 |
Buy |
123915.00 |
Peters Richard |
| 2026-04-01 |
Buy |
30978.00 |
Hamill John P. |
| 2026-02-02 |
Buy |
28100.00 |
Gilad Oren |
| 2026-02-02 |
Buy |
5700.00 |
Hamill John P. |
| 2025-12-11 |
Buy |
21459.00 |
Duey Marc |
| 2025-12-11 |
Buy |
21459.00 |
Gilad Oren |
| 2025-12-11 |
Buy |
5000.00 |
Hamill John P. |
| 2025-04-04 |
Buy |
3003.00 |
Gilad Oren |
| 2024-10-24 |
Buy |
500.00 |
Gilad Oren |
| 2024-10-17 |
Buy |
30000.00 |
Duey Marc |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
2 |
Apr 07, 2026 |
| 4 |
Insider transactions |
1 |
Apr 01, 2026 |
| 4 |
Insider transactions |
1 |
Apr 01, 2026 |
| 8-k |
8K-related |
14 |
Apr 01, 2026 |
| schedule |
Other |
2 |
Apr 01, 2026 |
| 8-k |
8K-related |
51 |
Mar 30, 2026 |
| 424b3 |
Other |
2 |
Mar 19, 2026 |
| s-3/a |
Other |
2 |
Mar 17, 2026 |
| 8-k |
8K-related |
42 |
Mar 16, 2026 |
| 10-k |
Annual reports |
84 |
Mar 16, 2026 |